Report
EUR 13.66 For Business Accounts Only

An unfavourable environment weighs on RITE AID CORP., which sees a downgrade to Negative

The independent financial analyst theScreener just requalified the general evaluation of RITE AID CORP. (US), active in the Drug Retailers industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Negative. As of the analysis date April 16, 2019, the closing price was USD 0.45 and its target price was estimated at USD 0.43.
Underlying
Rite Aid Corporation

Rite Aid is a pharmacy retail healthcare company. The company operates through its two reportable segments: Retail Pharmacy, which sells brand and generic prescription drugs, as well as an assortment of front-end products including health and beauty aids, personal care products, seasonal merchandise, and a private brand product line; and Pharmacy Services, which provides pharmacy benefit management (PBM) options through its EnvisionRxOption and MedTrak PBMs, as well as mail-order and specialty pharmacy services and cash pay infertility discount drug program via Design Rx, among others.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch